213 related articles for article (PubMed ID: 20407894)
1. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma.
Cho CH; Hwang WL; Cheng SB; Lee TY; Teng CL
Ann Hematol; 2011 Jan; 90(1):111-2. PubMed ID: 20407894
[No Abstract] [Full Text] [Related]
2. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease.
Zachou K; Dalekos GN
Liver Int; 2011 Mar; 31(3):277-9. PubMed ID: 21281426
[No Abstract] [Full Text] [Related]
4. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
Zhang B; Wang J; Xu W; Wang L; Ni W
Onkologie; 2010; 33(10):537-9. PubMed ID: 20926902
[TBL] [Abstract][Full Text] [Related]
5. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection.
Watanabe M; Shibuya A; Tsunoda Y; Danbara M; Ishii R; Ohsaka M; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Horie R; Higashihara M; Koizumi W
Liver Int; 2011 Mar; 31(3):340-7. PubMed ID: 21134110
[TBL] [Abstract][Full Text] [Related]
6. Reply to S. Kusumoto et al.
Huang YH; Lin HC; Lee SD
J Clin Oncol; 2013 Dec; 31(35):4481. PubMed ID: 24220562
[No Abstract] [Full Text] [Related]
7. Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment.
Kim MG; Park SY; Kim EJ; Kim YM; Kim HY; Lee YK; Zang DY; Kim HJ
Acta Haematol; 2011; 125(3):121-4. PubMed ID: 21150178
[TBL] [Abstract][Full Text] [Related]
8. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?
Kusumoto S; Tanaka Y; Mizokami M; Ueda R
J Clin Oncol; 2013 Dec; 31(35):4480. PubMed ID: 24220561
[No Abstract] [Full Text] [Related]
9. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
Liu CY; Chandrasekar PH; Masood A; Schiffer CA
J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.
Thompson PA; Tam CS; Thursky K; Seymour JF
Leuk Lymphoma; 2010 Sep; 51(9):1592-5. PubMed ID: 20807092
[No Abstract] [Full Text] [Related]
11. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance.
Chew E; Thursky K; Seymour JF
Leuk Lymphoma; 2014 Apr; 55(4):938-9. PubMed ID: 23772645
[No Abstract] [Full Text] [Related]
12. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
Coiffier B
Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
[TBL] [Abstract][Full Text] [Related]
13. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma.
Uchiyama M; Tamai Y; Ikeda T
Int J Infect Dis; 2010 Mar; 14(3):e265-6. PubMed ID: 19665406
[No Abstract] [Full Text] [Related]
14. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
[TBL] [Abstract][Full Text] [Related]
15. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.
Niscola P; Del Principe MI; Maurillo L; Venditti A; Buccisano F; Piccioni D; Amadori S; Del Poeta G
Leukemia; 2005 Oct; 19(10):1840-1. PubMed ID: 16094417
[No Abstract] [Full Text] [Related]
16. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab.
Salman-Monte TC; Lisbona MP; García-Retortillo M; Maymó J
Reumatol Clin; 2014; 10(3):196-7. PubMed ID: 24054835
[No Abstract] [Full Text] [Related]
17. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
He YF; Li YH; Wang FH; Jiang WQ; Xu RH; Sun XF; Xia ZJ; Huang HQ; Lin TY; Zhang L; Bao SP; He YJ; Guan ZZ
Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B reactivation and rituximab in the oncology practice.
Villadolid J; Laplant KD; Markham MJ; Nelson DR; George TJ
Oncologist; 2010; 15(10):1113-21. PubMed ID: 20930099
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma.
Yang SH; Kuo SH
Ann Hematol; 2008 Apr; 87(4):325-7. PubMed ID: 17932671
[No Abstract] [Full Text] [Related]
20. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Mitroulis I; Hatzara C; Kandili A; Hadziyannis E; Vassilopoulos D
Ann Rheum Dis; 2013 Feb; 72(2):308-10. PubMed ID: 22930597
[No Abstract] [Full Text] [Related]
[Next] [New Search]
